LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM; K i =226 nM). LIT-001 improves social interaction in a mouse model of autismIn VitroIn vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoLIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Oprm1 –/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background) Dosage: 10, 20 mg/kg Administration: i.p. Result: Alleviated core symptoms in the context of ASD.Form:SolidIC50& Target:EC50: 55 nM (OT-R), Ki: 226 nM (OT-R). Specification: 0.98 Molecular Formula: C30H34F3N7O4S Molecular Weight: 645.7 PubChem CID: 145711713
- UPC:
- 51142432
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- L646912-25mg
- CAS:
- 2245072-21-1
- Product Size:
- 25mg
